ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in
case of bcl-2 overexpression in non previously treated patients aged 60 years or less with
low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal
is to obtain a 15% increase of event-free survival at 2 years.